Parametric Portfolio Associates LLC grew its stake in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 0.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 194,227 shares of the biopharmaceutical company’s stock after purchasing an additional 1,245 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.16% of Keryx Biopharmaceuticals worth $1,404,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. UBS Asset Management Americas Inc. lifted its stake in shares of Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 102 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 300 shares during the period. Rhumbline Advisers raised its holdings in shares of Keryx Biopharmaceuticals by 0.3% in the second quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 335 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 590 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Keryx Biopharmaceuticals by 1.0% in the first quarter. Bank of America Corp DE now owns 108,558 shares of the biopharmaceutical company’s stock worth $669,000 after buying an additional 1,058 shares during the period. 65.44% of the stock is owned by institutional investors and hedge funds.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at $4.78 on Wednesday. Keryx Biopharmaceuticals, Inc. has a fifty-two week low of $4.47 and a fifty-two week high of $8.38. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The company’s revenue for the quarter was up 138.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) earnings per share. equities analysts predict that Keryx Biopharmaceuticals, Inc. will post -1.34 earnings per share for the current year.

WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/15/parametric-portfolio-associates-llc-has-1-40-million-stake-in-keryx-biopharmaceuticals-inc-kerx.html.

Several brokerages have recently weighed in on KERX. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Stifel Nicolaus reduced their price target on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th. BidaskClub downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Maxim Group set a $9.00 price target on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $7.35.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.